CRISPR Therapeutics (CRSP) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.94
- Estimate
- -$1.18
- Surprise
- +20.6%
- Revenue (period 2026-06-30)
- $10.2M
- Score today
- 5.2/10
Revenue source: xbrl.
How the report landed
CRISPR Therapeutics (CRSP) reported a narrower loss than forecast — adjusted EPS of -$0.94 against the -$1.18 estimate (a 20.6% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CRSP Sell at 5.2/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +20.6% surprise compares with a +3.6% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Quality below floor (1.8 < 4.0)
- NEWS_SOFT:LEADERSHIP_CHANGE
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $55.47
- Price target
- $77.07
- Stop
- $51.59
- Upside to target
- +38.9%
- Reward-to-risk
- 2.7:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
CRSP at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $5.23B
- P/E (fwd)
- -15.2
- 52-week range
- $44.12–$65.98
- Off 52-week high
- 15.9%
- RSI (14)
- 56
- Volume vs avg
- 0.22×
- Score today
- 5.2/10